Breast cancer in an 18-year-old female: A fatal case report and literature review

Cancer Biol Ther. 2018 Jul 3;19(7):543-548. doi: 10.1080/15384047.2017.1416931.

Abstract

Breast cancer (BC) is the most frequent malignancy in both pre- and postmenopausal women. However, it is exceedingly rare in very young patients, and especially in adolescents. Herein, we report a case of an 18-year-old female diagnosed with invasive BC. The proband had been found to be negative for BC in close family members. A common BC genetic screening test for the Polish population did not detect any known founder mutations in the BRCA1 gene. Further evaluation identified a p.Ile157Thr (I157T) mutation in the CHEK2 gene, a p.Ala1991Val (A1991V) variant of unknown significance in the BRCA2 gene, p.Lys751Gln (K751Q) variant in the XPD (ERCC2) gene, and a homozygous p.Glu1008Ter (E1008*) mutation in the NOD2 gene. No other mutation had been found by next generation sequencing in major BC high-risk susceptibility genes BRCA1, BRCA2, as well as 92 other genes. To date, all these found alterations have been considered as low to moderate risk factors in the general population and moderate risk factors in younger women (<35 years of age). There are no previous articles relating low and moderate risk gene mutations to very young onset (below 20 years) BC with a fatal outcome. In our patient, a possible cumulative or synergistic risk effect for these 4 alterations, and a mutation in the NOD2 gene in particular, of which both presumably healthy parents were found to be carriers, is suggested.

Keywords: BRCA2 gene; CHEK2 gene; NOD2 gene; XPD gene; adolescent; breast cancer; next generation sequencing.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adolescent
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • BRCA2 Protein
  • Breast Neoplasms / complications
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / genetics*
  • Breast Neoplasms / pathology
  • Checkpoint Kinase 2
  • Cyclophosphamide / therapeutic use
  • Doxorubicin / therapeutic use
  • Fatal Outcome
  • Female
  • Genetic Carrier Screening
  • Genetic Predisposition to Disease*
  • Heterozygote
  • Humans
  • Liver Neoplasms / complications
  • Liver Neoplasms / genetics
  • Liver Neoplasms / secondary
  • Lung Neoplasms / complications
  • Lung Neoplasms / genetics
  • Lung Neoplasms / secondary
  • Male
  • Multiple Organ Failure / etiology*
  • Mutation
  • Nod2 Signaling Adaptor Protein / genetics
  • Parents
  • Taxoids / therapeutic use
  • Xeroderma Pigmentosum Group D Protein / genetics

Substances

  • BRCA2 Protein
  • BRCA2 protein, human
  • NOD2 protein, human
  • Nod2 Signaling Adaptor Protein
  • Taxoids
  • Doxorubicin
  • Cyclophosphamide
  • Checkpoint Kinase 2
  • CHEK2 protein, human
  • Xeroderma Pigmentosum Group D Protein
  • ERCC2 protein, human

Supplementary concepts

  • TAC protocol

Grants and funding

The European Union from the European Regional Development Fund.